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Supplementary Figure 1
5GF cytokine combination results in increased frequency of SRC. CD34+ cord blood progenitors 
were cultured for 17 days in varying cytokine combinations and limiting dilution transplants performed as 
described previously with 5GF versus 4GF to determine SRC frequency (SRC frequency per 106 starting 
cells).  *SFT63 is reference group for p values. 
(SFT=SCF, Flt3L, TPO; SFT6=SFT + IL6; SFT3= SFT + IL-3; SFT63 (5GF)= SCF, Flt3L, TPO, IL-6, IL-3)
Notch-mediated Expansion of Human Cord Blood Progenitor Cells Capable of 
Rapid Myeloid Reconstitution
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Ronald L. Manger, Irwin D. Bernstein
020
40
60
80
17-22 weeks post infusion
C
D
4
5
%
0
1
2
3
4
0.5
3 weeks post infusion
C
D
4
5
%
Human Engraftment in the Marrow of
Primary and Secondary Recipients
Supplementary Figure 2; Delaney et al
Long-term repopulating cells are maintained after Notch-mediated ex vivo expansion of cord 
blood CD34+ progenitor cells.  CD34+ cells were cultured for 16 days  as described and infused into 
sublethally irradiated NOD/SCID IL-2Rγnull mice. (a) Overall human engraftment in primary recipients at 
the time of sacrifice (17 – 22 weeks) and collection of whole marrow for secondary transplantation. Bar at 
the mean. (b) Overall human engraftment in the marrow of secondary NOD/SCID IL-2Rγnull recipients at 3 
weeks post infusion of primary recipient marrow. Mice were considered engrafted if they had ≥0.5% 
human CD45+ cells. 
Supplemental Table 1: Demograpahics, HLA and Infused Cell Doses 
 Ex vivo Expansion 
(N=10) 
Conventional Double 
(N=20) 
Male/Female 5/5 9/11 
Median Age in years (range) 27.5 (3 to 43) 21.5 (10 to 42) 
Median Weight in kg (range) 61.5 (16 to 79) 69.5 (32 to 110) 
Disease   
 AML 8 9 
 ALL (Ph+) 1 (1) 7 (4) 
 Bi-phenotypic 1 0 
 CML 0 3 
 MDS 0 1 
Disease Status   
 CR1 (morphologic) 5 7 
 ≥ CR2 (morphologic)  5 9 
 Chloroma 3 0 
 MRD (flow) 1 7 
HLA Matching (HLA-A, B and DRB1)   
Unmanipulated CBU: patient   
4/6 7 26 
5/6 3 11 
6/6 0 3 
Expanded CBU: patient   
4/6 6 N/A 
5/6 4 N/A 
Infused Cell Doses   
Non-manipulated units   
 Total TNC/kg x107; avg (range) 3.3 (1.5 to 6.3) 4.3 (2.2 to 11.2) 
 Total CD34/kg x105; avg (range) 2.4 (0.6 to 5.4) 3.1 (1.3 to 5.4) 
Ex vivo Expanded Unit  - 
 TNC/kg x107 per unit; avg (range) 4.6 (0.6 to 9.1) N/A 
 CD34/kg x105 per unit; avg (range) 60.3 (9.2 to 133) N/A 
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Supplementary Table 2: Expanded Unit Characteristics
Supplemental Table 2: Expanded Unit Characteristics
Patient # Pre-Freeze Post-selection Recovery Starting Purity Post-expansion 
 TNC (x 109) 
CD34 
(x 106) 
Abs # CD34 
(x 106) CD34 (%) CD34 (%) Viability 
Abs # CD34 
(x 106) 
Fold 
Increase 
1 1.5 12.5 5.5 44 61 70 1440 261 
2 1.3 7.9 1.6 20 45 86 154 96 
3 1.3 7.2 1.5 21 83 77 60 41 
4 1.3 3.4 1.5 44 37 73 113 74 
5 1.2 3.6 1.3 36 54 66 111 87 
6 2.4 8.2 2.6 32 42 87 977 382 
7 1.2 3.6 2.0 56 46 73 145 72 
8 1.9 n/a 4.1 n/a 60 76 229 57 
9 1.7 5.8 1.7 29 41 81 810 471 
10 3.6 28.0 5.4 20 54 76 537 99 
Mean 1.6 7.6 2.7 36 52 76 457 164 
Sem 0.14 1.2 0.52 4.5 4.3 2.1 149 48 
*n/a = not available 
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Percent 
(range) 
Cells/kg 
(range) 
CD34 14.5  (6.2 - 26) 6.1 x 106    (0.9 -13.6)  
CD7 8.1    (5.9 – 12)  3.9 x 106   (0.3 - 9.1) 
CD14 11.3  (1.8 – 23) 5.6 x 106    (0.1 - 14.6) 
CD15 20.5  (6 – 36) 9.0 x 106   (1.1 - 23)    
CD34+/56+ 2.9    (1.4 – 5.8) 1.7 x 106    (0.08 – 5.3) 
CD3-/CD16+/56+ 5.4    (2.2 – 13.6) 2.7 x 106   (0.1 – 12.4) 
CD20 0.1    (0 – 0.2) 3.6 x 104   (0 – 14) 
CD3 0.2    (0 – 0.6) 4.8 x 104   (0 – 13) 
CD4lo/CD3neg/CD8neg 40.6  (16 – 67) 1.7 x 107   (0.2 – 6.1) 
CD8 0.1    (0 – 0.5) 3.4 x 104   (0 – 17) 
 
Supplementary Table 3: Expanded Unit Selected Immunophenotyping
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SUPPLEMENTARY METHODS (Delaney, et al) 
 
cGMP purification of stable Delta1ext-IgG 
 
Generation of Cell Bank. A candidate cell line was quarantined within the cGMP 
production facility. Following screening for specific isotype and freedom from microbial 
contamination cells were weaned for growth with HyQ SFM4MAb-Utility media (Hyclone) 
supplemented with 2 mM L-glutamine (JRH Biosciences) and 1% irradiated fetal bovine 
serum (Hyclone). Both a master working cell bank and working cell bank were 
generated, tested, and qualified. Cell banks were then stored in controlled and isolated 
liquid nitrogen freezers reserved exclusively for qualified clinical production cultures. 
 
Cell Culture Process. To initiate a production run, vials from the working cell bank were 
thawed then placed into culture in an 125 ml spinner flask containing 50 ml complete 
media (HyQ SFM4MAb-Utility media, Hyclone) supplemented with 2 mM L-glutamine 
(JRH Biosciences) and 1% irradiated fetal bovine serum (Hyclone). The culture was 
grownat 37oC with a 5% CO2 modified atmosphereand expanded into increasingly 
larger spinner flask cultures as required to provide a minimal initial seed of 30 liters at 
3.5 x 105cells/ml to initiate production within a 110 liter stainless steel bioreactor 
(Applikon). Bioreactor control set points were adjusted to 37o C, pH 7.0, dissolved O2 at 
10%, and impeller agitation at 60 RPM. When sufficient cell density was reached the 
bioreactor culture was expanded to 85 liters. At the end of the bioreactor growth cycle, 
as indicated by a decline in cell viability approaching 20%, the run was terminated and 
bulk crude product (conditioned medium) harvested. At harvest quality control testing 
was performed for mycoplasma, potential viral contaminants by electron microscopy, 
and sterility (bioburden). 
 
Purification. Cell removal and clarification steps were conducted by harvesting the 
conditioned medium from the Applikon bioreactor and processing through bulk filtration 
(Cuno Maximizer filters, 90M05 Cartridge and 90ZA BioCap). Clarified harvest was 
then stored frozen until further processing. Samples of clarified harvest were tested for 
product concentration (ELISA) and endotoxin (Charles River Endosafe KTA LAL). 
 
The clarified, conditioned media was then thawed, pooled, adjusted (pH and conductivity 
to match Protein A chromatography equilibration buffer; 50 mM Sodium Phosphate, 220 
mM Sodium Chloride, pH 7.2), andloaded onto an equilibrated Protein A affinity column 
(Pharmacia Index 100, 10 cm diameter column, packed to a bed height of 6 cm with 
rProtein A Sepharose Fast Flow, Amersham Biosciences). Post high salt elution (10mM 
Tris, 4M MgCl2, pH 6.7) the eluate was adjusted to pH 3.8+/-0.05, held for 30 minutes 
for potential viral contaminant inactivation, and then adjusted to pH 7.0+/-0.2. 
 
An Index 100 column (Pharmacia) packed with G25 Sephadex (GE Healthcare) 
equilibrated with 10 mM Tris, 5% glycerol, pH 7.5 was then used for an additional 
purification step and buffer exchange. This was followed by filtration for potential viral 
contaminants through a Viresolve NFR size exclusion filter (Millipore). Tangental flow 
filtration was performed to exchange product into final buffer formulation (10 mM Tris, 4 
M Mg Cl2, pH 6.7) and a target concentration of 0.35 mg/ml. Product was 0.2 um 
filtered and aseptically filled into single dose glass vials then stored at -20o C until use. 
Quality control testing of bulk purified and final vialed product included assays for purity, 
identity, functionality, sterility, and endotoxin. 
 
